Developer docs
API playgroundTry for free, no card

Search company profiles

Cidara Therapeutics

Full company profile

uuid0000ewt

Namestring
Cidara Therapeutics
Legal namestring
Merck & Co., Inc.
Websiteurl
cidara.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Cidara Therapeutics was a San Diego-based, clinical-stage biotechnology company founded in 2012 that developed long-acting therapeutics for serious diseases using its proprietary Cloudbreak drug-Fc conjugate platform. The company's core technology enabled the design of targeted immunotherapies with potential applications across oncology, viral infections, and autoimmune conditions. Its lead asset, CD388, was a non-vaccine, single-dose antiviral therapeutic designed for universal prevention of seasonal and pandemic influenza, demonstrated up to 76.1% efficacy against influenza A and B in Phase 2b trials in unvaccinated adults. The product received both FDA Fast Track and Breakthrough Therapy designations, and advanced into a Phase 3 ANCHOR trial that enrolled 6,000 participants across the US and UK. The company also had rezafungin, an antifungal candidate, in its pipeline.

Cidara operated as a pre-commercial biotech with no approved products on market, generating no product revenue. Capital was raised through a combination of federal grants (notably a $339M BARDA award in October 2025), public equity offerings (a $350M upsized offering in June 2025), and private placements (a $105M round led by Venrock Healthcare Capital Partners in November 2024). The company's primary customer-facing activity was scientific communication, investor relations, and regulatory engagement rather than commercial sales. Targeted customer segments included high-risk influenza populations (elderly, immunocompromised) and unvaccinated adults, with go-to-market planning dependent on FDA approval and pharmaceutical distribution channels.

In November 2025, Merck & Co. announced a definitive agreement to acquire Cidara for approximately $9.2 billion ($221.50 per share in cash), motivated by CD388's potential to expand Merck's respiratory pipeline and offset upcoming Keytruda patent expirations. The acquisition was completed on January 7, 2026, with approximately 85.96% of shares tendered, making Cidara a wholly owned subsidiary of Merck delisted from the Nasdaq Global Market.

Short descriptiontext

Cidara Therapeutics was a San Diego-based clinical-stage biotech (founded 2012) that developed long-acting antivirals using its proprietary Cloudbreak drug-Fc conjugate platform. Its lead candidate CD388, a non-vaccine influenza preventative demonstrating 76.1% efficacy in Phase 2b, was acquired by Merck for $9.2 billion in January 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral therapeutics, drug-Fc conjugates, influenza prevention, immunotherapy platform, antifungal drugs
Industry1 code
PRIMARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
Product category
Antiviral Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Grant Funding
TypeLicensing Royalties
Description

Federal funding from BARDA (Biomedical Advanced Research and Development Authority) awarded $339 million to support manufacturing and clinical development of CD388

biospace.com
2Public Equity Offerings
TypeOne Time License
Description

Generated capital through public stock offerings - $350 million upsized public offering of common stock in June 2025

marketscreener.com
3Private Placement
TypeOne Time License
Description

$105 million private placement led by Venrock Healthcare Capital Partners for R&D of product candidates

investing.com
4Public Offering
TypeOne Time License
Description

Approximately $17.5 million gross proceeds from public offerings of common stock and Series X Convertible Preferred Stock in March 2023

biospace.com
5Acquisition Proceeds
TypeOne Time License
Description

Company was acquired by Merck & Co. for $9.2 billion in November 2025, representing value realization for shareholders

sandiegouniontribune.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cidara Therapeutics develops long-acting targeted immunotherapies for serious diseases using its proprietary Cloudbreak drug-Fc conjugate platform. Its lead asset, CD388, is a non-vaccine influenza preventative therapeutic that demonstrated up to 76.1% protection against influenza A and B in Phase 2b trials and is being evaluated in the Phase 3 ANCHOR trial. The pipeline also includes rezafungin, an antifungal candidate for serious invasive fungal infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 76.1% prevention efficacy against influenza A and B in unvaccinated adults (Phase 2b trial)
+2 more records
Product overview1 text field

Cidara Therapeutics is a biotechnology company that developed long-acting therapeutics for serious diseases using its proprietary Cloudbreak drug-Fc conjugate platform. The company's primary product candidate was CD388, a non-vaccine influenza preventative therapeutic in Phase 3 trials, which demonstrated up to 76.1% efficacy in Phase 2b studies. The company also had rezafungin (antifungal) in its pipeline. In January 2026, Cidara was acquired by Merck & Co. for $9.2 billion.

Product and service3 records
1CD388
CategoryAntiviral Therapeutic
Description

A long-acting antiviral drug-Fc conjugate therapeutic designed for universal prevention of seasonal and pandemic influenza. Administered as a single dose for season-long protection. Phase 2b data showed up to 76.1% prevention efficacy against influenza A and B in unvaccinated adults. Holds FDA Fast Track and Breakthrough Therapy designations. Intended for adults and high-risk populations including elderly and immunocompromised individuals.

2Rezafungin
CategoryAntifungal Therapeutic
Description

An antifungal candidate developed for treatment of serious invasive fungal diseases. Part of Cidara's pipeline of long-acting therapeutics built on the Cloudbreak drug-Fc conjugate platform.

3Cloudbreak Platform
CategoryDrug Development Platform
Description

Proprietary drug-Fc conjugate technology platform that enables development of targeted therapeutics for serious diseases including oncology, viral infections, and autoimmune conditions. Serves as the foundation for Cidara's product pipeline.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-03
Description

Previously partnered with Janssen for CD388 development. Cidara regained full rights to the asset in 2024 after Janssen wound down its infectious disease and vaccine R&D operations

Strategic tierCoreTypeStrategic or Co-development Partner
Description

hVIVO contributed significantly to the development and clinical trials of CD388, providing clinical trial services and expertise in human challenge studies for the antiviral candidate

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets XOFLUZA (baloxavir marboxil), an oral antiviral for influenza treatment and post-exposure prophylaxis, in partnership with Shionogi. Most directly comparable to CD388 as an antiviral influenza agent, though CD388's prevention positioning and long-acting mechanism are differentiated.

TypeDirect peer
Description

Originated baloxavir marboxil (XOFLUZA) and develops infectious disease therapeutics, including antivirals for influenza. Comparable as a developer of novel antiviral influenza agents, with similar therapeutic area focus and regulatory pathway experience.

TypeDirect peer
Description

Develops mRNA-based influenza vaccines (mRNA-1010 and next-gen candidates) targeting improved efficacy over traditional flu vaccines. Directly competes with CD388 in the influenza prevention market with a differentiated mRNA technology platform.

TypeDirect peer
Description

Developing mRNA-based influenza vaccines through partnership with Pfizer, targeting improved strain coverage and efficacy. Competes with CD388 in seasonal flu prevention with a Phase 3-stage mRNA vaccine candidate.

TypeBroad incumbent
Description

World's largest influenza vaccine manufacturer (Fluad, Fluzone, etc.) and a major incumbent in flu prevention. Competes with CD388 in the seasonal flu market as the dominant vaccine supplier, particularly for high-risk elderly populations.

6Sanofi Pasteur
TypeBroad incumbent
Description

Major flu vaccine manufacturer with Fluzone High-Dose and Fluzone HD, particularly strong in elderly and high-risk segments. Competes with CD388 in the high-risk flu prevention market that Cidara is targeting.

TypeBroad incumbent
Description

Markets Fluarix and other seasonal influenza vaccines globally. Competes with CD388 as an established flu vaccine manufacturer with broad distribution and payer access.

TypeDirect peer
Description

Develops protein nanoparticle-based influenza vaccines, including a Phase 3-stage candidate. Competes with CD388 in the flu prevention market with a differentiated vaccine platform targeting improved efficacy.

TypeEmerging player
Description

Clinical-stage infectious disease company developing antiviral therapeutics, including for influenza and other respiratory viruses. Comparable as a focused antiviral developer with platform technology targeting serious viral infections.

TypeEmerging player
Description

Develops mRNA-based therapeutics for infectious diseases, including influenza vaccine candidates. Comparable as an emerging platform-based developer of novel infectious disease therapeutics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cidara Therapeutics

Antiviral Pharmaceuticalscidara.com

Cidara Therapeutics was a San Diego-based clinical-stage biotech (founded 2012) that developed long-acting antivirals using its proprietary Cloudbreak drug-Fc conjugate platform. Its lead candidate CD388, a non-vaccine influenza preventative demonstrating 76.1% efficacy in Phase 2b, was acquired by Merck for $9.2 billion in January 2026.

What Cidara Therapeutics does

Cidara Therapeutics was a San Diego-based, clinical-stage biotechnology company founded in 2012 that developed long-acting therapeutics for serious diseases using its proprietary Cloudbreak drug-Fc conjugate platform. The company's core technology enabled the design of targeted immunotherapies with potential applications across oncology, viral infections, and autoimmune conditions. Its lead asset, CD388, was a non-vaccine, single-dose antiviral therapeutic designed for universal prevention of seasonal and pandemic influenza, demonstrated up to 76.1% efficacy against influenza A and B in Phase 2b trials in unvaccinated adults. The product received both FDA Fast Track and Breakthrough Therapy designations, and advanced into a Phase 3 ANCHOR trial that enrolled 6,000 participants across the US and UK. The company also had rezafungin, an antifungal candidate, in its pipeline.

Cidara operated as a pre-commercial biotech with no approved products on market, generating no product revenue. Capital was raised through a combination of federal grants (notably a $339M BARDA award in October 2025), public equity offerings (a $350M upsized offering in June 2025), and private placements (a $105M round led by Venrock Healthcare Capital Partners in November 2024). The company's primary customer-facing activity was scientific communication, investor relations, and regulatory engagement rather than commercial sales. Targeted customer segments included high-risk influenza populations (elderly, immunocompromised) and unvaccinated adults, with go-to-market planning dependent on FDA approval and pharmaceutical distribution channels.

In November 2025, Merck & Co. announced a definitive agreement to acquire Cidara for approximately $9.2 billion ($221.50 per share in cash), motivated by CD388's potential to expand Merck's respiratory pipeline and offset upcoming Keytruda patent expirations. The acquisition was completed on January 7, 2026, with approximately 85.96% of shares tendered, making Cidara a wholly owned subsidiary of Merck delisted from the Nasdaq Global Market.

Cidara Therapeutics firmographics

Firmographics
Name
Cidara Therapeutics
Legal name
Merck & Co., Inc.
Website
https://cidara.com
Company type
Public
Founded year
2013
Operating status
Acquired
Headcount range
11–50 employees
Short description
Cidara Therapeutics was a San Diego-based clinical-stage biotech (founded 2012) that developed long-acting antivirals using its proprietary Cloudbreak drug-Fc conjugate platform. Its lead candidate CD388, a non-vaccine influenza preventative demonstrating 76.1% efficacy in Phase 2b, was acquired by Merck for $9.2 billion in January 2026.
Ownership category
akta.pro rank

Cidara Therapeutics industry classification

Industry
Product category
Antiviral Pharmaceuticals
akta.pro industry
PRIMARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Antiviral therapeutics
  • Drug-Fc conjugates
  • Influenza prevention
  • Immunotherapy platform
  • Antifungal drugs

Where Cidara Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cidara Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations

Revenue model

  1. Grant Funding: Federal funding from BARDA (Biomedical Advanced Research and Development Authority) awarded $339 million to support manufacturing and clinical development of CD388
  2. Public Equity Offerings: Generated capital through public stock offerings - $350 million upsized public offering of common stock in June 2025
  3. Private Placement: $105 million private placement led by Venrock Healthcare Capital Partners for R&D of product candidates
  4. Public Offering: Approximately $17.5 million gross proceeds from public offerings of common stock and Series X Convertible Preferred Stock in March 2023
  5. Acquisition Proceeds: Company was acquired by Merck & Co. for $9.2 billion in November 2025, representing value realization for shareholders

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Cidara Therapeutics product offering

Product offering

Core offering

Cidara Therapeutics develops long-acting targeted immunotherapies for serious diseases using its proprietary Cloudbreak drug-Fc conjugate platform. Its lead asset, CD388, is a non-vaccine influenza preventative therapeutic that demonstrated up to 76.1% protection against influenza A and B in Phase 2b trials and is being evaluated in the Phase 3 ANCHOR trial. The pipeline also includes rezafungin, an antifungal candidate for serious invasive fungal infections.

Product overview

Cidara Therapeutics is a biotechnology company that developed long-acting therapeutics for serious diseases using its proprietary Cloudbreak drug-Fc conjugate platform. The company's primary product candidate was CD388, a non-vaccine influenza preventative therapeutic in Phase 3 trials, which demonstrated up to 76.1% efficacy in Phase 2b studies. The company also had rezafungin (antifungal) in its pipeline. In January 2026, Cidara was acquired by Merck & Co. for $9.2 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • CD388 A long-acting antiviral drug-Fc conjugate therapeutic designed for universal prevention of seasonal and pandemic influenza. Administered as a single dose for season-long protection. Phase 2b data showed up to 76.1% prevention efficacy against influenza A and B in unvaccinated adults. Holds FDA Fast Track and Breakthrough Therapy designations. Intended for adults and high-risk populations including elderly and immunocompromised individuals.
  • Rezafungin An antifungal candidate developed for treatment of serious invasive fungal diseases. Part of Cidara's pipeline of long-acting therapeutics built on the Cloudbreak drug-Fc conjugate platform.
  • Cloudbreak Platform Proprietary drug-Fc conjugate technology platform that enables development of targeted therapeutics for serious diseases including oncology, viral infections, and autoimmune conditions. Serves as the foundation for Cidara's product pipeline.

Quantifiable outcome

  • 76.1% prevention efficacy against influenza A and B in unvaccinated adults (Phase 2b trial)
  • +2 more outcomes

Companies that use Cidara Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Cidara Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cidara Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Janssen (Johnson & Johnson)minorStrategic or Co-development Partner · 3 October 2025Previously partnered with Janssen for CD388 development. Cidara regained full rights to the asset in 2024 after Janssen wound down its infectious disease and vaccine R&D operations
  • hVIVO plccoreStrategic or Co-development PartnerhVIVO contributed significantly to the development and clinical trials of CD388, providing clinical trial services and expertise in human challenge studies for the antiviral candidate

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Cidara Therapeutics competitors and assessment

Company assessment

Direct peers

  • Roche / Genentech: Markets XOFLUZA (baloxavir marboxil), an oral antiviral for influenza treatment and post-exposure prophylaxis, in partnership with Shionogi. Most directly comparable to CD388 as an antiviral influenza agent, though CD388's prevention positioning and long-acting mechanism are differentiated.
  • Shionogi: Originated baloxavir marboxil (XOFLUZA) and develops infectious disease therapeutics, including antivirals for influenza. Comparable as a developer of novel antiviral influenza agents, with similar therapeutic area focus and regulatory pathway experience.
  • Moderna: Develops mRNA-based influenza vaccines (mRNA-1010 and next-gen candidates) targeting improved efficacy over traditional flu vaccines. Directly competes with CD388 in the influenza prevention market with a differentiated mRNA technology platform.
  • BioNTech: Developing mRNA-based influenza vaccines through partnership with Pfizer, targeting improved strain coverage and efficacy. Competes with CD388 in seasonal flu prevention with a Phase 3-stage mRNA vaccine candidate.
  • Novavax: Develops protein nanoparticle-based influenza vaccines, including a Phase 3-stage candidate. Competes with CD388 in the flu prevention market with a differentiated vaccine platform targeting improved efficacy.

Broad incumbents

  • CSL Seqirus: World's largest influenza vaccine manufacturer (Fluad, Fluzone, etc.) and a major incumbent in flu prevention. Competes with CD388 in the seasonal flu market as the dominant vaccine supplier, particularly for high-risk elderly populations.
  • Sanofi Pasteur: Major flu vaccine manufacturer with Fluzone High-Dose and Fluzone HD, particularly strong in elderly and high-risk segments. Competes with CD388 in the high-risk flu prevention market that Cidara is targeting.
  • GSK: Markets Fluarix and other seasonal influenza vaccines globally. Competes with CD388 as an established flu vaccine manufacturer with broad distribution and payer access.

Emerging players

  • Vir Biotechnology: Clinical-stage infectious disease company developing antiviral therapeutics, including for influenza and other respiratory viruses. Comparable as a focused antiviral developer with platform technology targeting serious viral infections.
  • Arcturus Therapeutics: Develops mRNA-based therapeutics for infectious diseases, including influenza vaccine candidates. Comparable as an emerging platform-based developer of novel infectious disease therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Cidara Therapeutics social profiles

Digital presence

Cidara Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cidara Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Cidara Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cidara Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cidara Therapeutics

What does Cidara Therapeutics do?

Cidara Therapeutics develops long-acting targeted immunotherapies for serious diseases using its proprietary Cloudbreak drug-Fc conjugate platform. Its lead asset, CD388, is a non-vaccine influenza preventative therapeutic that demonstrated up to 76.1% protection against influenza A and B in Phase 2b trials and is being evaluated in the Phase 3 ANCHOR trial. The pipeline also includes rezafungin, an antifungal candidate for serious invasive fungal infections.

Is Cidara Therapeutics a public or private company?

Cidara Therapeutics is a public company. It is classified as corporate owned and is currently acquired.

When was Cidara Therapeutics founded?

Cidara Therapeutics was founded in 2013. It employs 11 to 50 people.

Where is Cidara Therapeutics based?

Cidara Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Cidara Therapeutics make money?

Five revenue lines are on record. Grant Funding is the primary driver. The others are public Equity Offerings, private Placement, public Offering and acquisition Proceeds.

Who are Cidara Therapeutics's main competitors?

Direct peers on record are Roche / Genentech, Shionogi, Moderna, BioNTech and Novavax. Broad incumbents are CSL Seqirus, Sanofi Pasteur and GSK. Emerging players are Vir Biotechnology and Arcturus Therapeutics.

Does Cidara Therapeutics have an API?

No public API is recorded for Cidara Therapeutics.

What industry is Cidara Therapeutics in?

Cidara Therapeutics's product category is Antiviral Pharmaceuticals. Its primary akta.pro industry code is HLAAACAB, Lentiviral Vector Gene Therapy Developers.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestorshangoutNever say goodbye too early, at - CYDY CytoDyn IncThe article analyzes the potential financing structure for a hypothetical $40–60 billion acquisition by Merck planned for 2027. It details a strategy involving bridge loans and permanent debt offerings to fund the deal, given Merck's limited cash reserves after recent expenditures on Cidara and Terns. The analysis highlights that such leverage would be aggressive but consistent with historical pharmaceutical M&A practices to offset the upcoming Keytruda patent cliff.BenzingaWhy Merck Just Slashed Its Profit Outlook By Nearly 50% - Merck & Co (NYSE:MRK)Merck & Co reported second-quarter adjusted losses of 13 cents per share, narrower than the expected 27-cent loss, with revenue rising 5% year over year to $16.61 billion, beating estimates, driven by Keytruda sales of $8.37 billion and strong growth in Winrevair. The company slashed its fiscal 2026 adjusted earnings guidance to $2.66–$2.76 per share from $5.04–$5.16, a reduction of nearly 50%, citing $3.62 per share in charges from the Cidara Therapeutics acquisition and $2.31 per share from the Terns acquisition. Merck simultaneously raised its revenue outlook to $66.3–$67.3 billion from the prior range of $65.8–$67.0 billion.BNNMerck posts better-than-expected second-quarter results on Keytruda strengthMerck reported Q2 revenue of $16.61 billion, beating estimates, driven by Keytruda sales of $8.37 billion. The company posted a 13-cent loss per share due to a $5.7 billion Terns acquisition charge, and raised its 2026 revenue forecast to $67.3 billion.MarketScreenerMerck posts better-than-expected second-quarter results on Keytruda strengthMerck reported Q2 revenue of $16.61 billion, beating estimates, and raised its 2026 revenue forecast to $66.3–67.3 billion. Keytruda sales rose 5% to $8.37 billion, while the company posted a 13-cent loss per share due to a $5.7 billion Terns acquisition charge.Labiotech.euMerck after Keytruda: what the pipeline looks likeMerck & Co. is executing a multi-billion-dollar acquisition strategy to prepare for the Keytruda patent cliff, with U.S. patents expiring from 2028 and the drug currently generating $31.7 billion in annual sales, nearly half the company's total revenue. The company completed approximately $26 billion in acquisitions between October 2025 and March 2026—Verona Pharma ($10B), Cidara Therapeutics ($9.2B), and Terns Pharmaceuticals ($6.7B)—to build new growth pillars in cardio-pulmonary medicine, immunology, and infectious disease alongside its expanding oncology business.The Mercury NewsSan Diego biotechs outperform San Francisco’s but can’t raise moneySan Diego experienced its third-lowest venture capital quarter of the decade at $804 million in Q2, despite local biotechs delivering superior returns compared to San Francisco and Boston. According to H.C. Wainwright & Co., San Diego biotechs achieved an 18.2% acquisition rate versus 12.3% in Boston and 9.5% in San Francisco, with investors earning $1.75 back per dollar versus $1.05 in the Bay Area. Notable exits include Cidara Therapeutics being sold to Merck for $9 billion after raising only $72 million, and Crinetics Pharmaceuticals in the process of a $10 billion acquisition by Vertex Pharmaceuticals.San Diego Union-TribuneSan Diego biotechs outperform San Francisco’s but can’t raise moneySan Diego biotech companies delivered stronger investment returns than their San Francisco and Boston counterparts in 2025, with an 18.2% acquisition rate versus 9.5% in San Francisco and $1.75 returned per dollar invested versus $1.05 in the Bay Area, yet the region raised only $804 million in the second quarter — the third-lowest of the decade. Major deals included a $171 million raise for Radar (AI-powered retail intelligence platform) and $111 million for Rakuten Medical's Alluminox cancer treatment platform, while A-tier venture funds in San Diego plummeted from 13 in 2022 to just two last year amid a broader shift of capital toward AI-focused San Francisco startups. Despite these strong local exits — including Cidara Therapeutics' $9 billion sale to Merck and Crinetics Pharmaceuticals' pending $10 billion acquisition by Vertex — investor attention remains concentrated elsewhere, with Bay Area startups raising over $93 billion in the same quarter.PR NewswireAcute Pain Market Forecast Signals Accelerated Growth at a CAGR of 12% During the Forecast Period (2026-2036), Driven by Novel Non-Opioid Therapies and Expanding Treatment Options | DelveInsightThe acute pain market is projected to grow at a 12% CAGR from 2026 to 2036, with the 7MM market valued at $4.5 billion in 2025. Growth is driven by non-opioid therapies and multimodal pain management, with emerging drugs like Rizatriptan and CPL-01 expected to launch.European BiotechnologyLeyden Labs adds €40m for intranasal flu preventionLeyden Labs raised €40m from investors including the Gates Foundation and ClavystBio to advance its intranasal antibody spray for influenza prevention. The funding supports its PanFlu program, which uses CR9114, with early human safety data from 143 volunteers. The company still needs clinical efficacy proof.